Loading...
Барьцалдаат спондилит өвчнийг секукинумабаар эмчилсэн тохиолдол
Зохиогч
Г.Бямбацэрэн
З.Ариунзаяа
Д.Оюунтамир
Б.Баасандулам
Б.Өнөрцэцэг
Он
2022 оны арван нэгдүгээр сарын 1
Төрөл
journal article
Journal
Эрүүл мэндийн шинжлэх ухаан
Volume
18
Issue
4
Start Page
123
End Page
125
ISSN
2959-6947
Хураангуй
Background: Axial spondyloarthritis (axSpA) is a potentially disabling inflammatory arthritis of the spine, usually presenting as chronic back pain, almost always before the age of 40. It is often associated with one or more of several articular and periarticular extraspinal features, including synovitis, enthesitis, and dactylitis. It may also be associated with several non articular features; these include uveitis, psoriasis, and inflammatory bowel disease (IBD). Patients frequently carry the gene for human leukocyte antigen (HLA) B27, and patients with active inflammatory disease may have evidence of an elevated acute phase response The risk factors for progression are male sex, being positive for human leukocyte antigen (HLA) B27, showing signs of inflammation on MRI of the sacroiliac(SI) joints, having elevated C-reactive protein (CRP),and history of smoking Case presentation: We describe the case of a 16-year-old men. He has back pain. There was a lot of pain at night. Six months earlier, I had been exposed to persistent back pain. The night’s pain was high, the lungs were covered in the back when they got up in the morning and the movement of the spine was restricted. When you move during the day, the pain is a little less. There were pain relievers, muscle release medications and physical therapies and the treatment was ineffective. Diagnosis: HLA-B27 /positive/ MRI L spine: 1. Shiny corner appearance at L1/5 2. Enthesitis of both sacroilit joints Treatment: Secukinumab, an anti-IL-17A monoclonal antibody, is an alternative to TNF inhibitors for patients with axial SpA. Secukinumab is administered in a dose of 150 mg by subcutaneous injection; patients should be treated weekly for four weeks as a loading dose, then once every four weeks thereafter.
Нэмэлт мэдээлэл
Бүрэн эх: https://journal.mnums.edu.mn/index.php/emsu/article/view/704
Эшлэл
Г.Бямбацэрэн, З.Ариунзаяа, Д.Оюунтамир, Б.Баасандулам, Б.Өнөрцэцэг. Барьцалдаат спондилит өвчнийг секукинумабаар эмчилсэн тохиолдол. Эрүүл мэндийн шинжлэх ухаан. 2022;18(4):123-125.
Түлхүүр үг